ALZAMEND NEURO INC (ALZN) Stock Overview
USA - NASDAQ:ALZN - US02262M6057 - Common Stock
ALZN Key Statistics, Chart & Performance
The current stock price of ALZN is 2.35 USD. In the past month the price decreased by -0.84%. In the past year, price decreased by -83.78%.
ALZN Latest News, Press Relases and Analysis
ALZN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.91 | 409.95B | ||
| AMGN | AMGEN INC | 13.91 | 163.30B | ||
| GILD | GILEAD SCIENCES INC | 15.91 | 152.76B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.74 | 107.45B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 64.39B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.64 | 61.13B | ||
| ARGX | ARGENX SE - ADR | 92.23 | 52.30B | ||
| INSM | INSMED INC | N/A | 35.49B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.15 | 34.99B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.95B | ||
| NTRA | NATERA INC | N/A | 25.89B | ||
| BIIB | BIOGEN INC | 9.16 | 21.50B |
Related stock screener links
About ALZN
Company Profile
Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing products for the treatment of neurodegenerative and psychiatric disorders. The company is headquartered in Atlanta, Georgia and currently employs 4 full-time employees. The company went IPO on 2021-06-15. The firm is focused on developing novel products for the treatment of Alzheimer's disease (Alzheimer's), bipolar disorder (BD), major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). The firm's pipeline consists of two novel therapeutic drug candidates: AL001, and ALZN002. AL001 is a patented ionic cocrystal technology delivering a therapeutic combination of lithium, salicylate and L-proline through three royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc., (the Licensor). AL001 is used for Alzheimer's, BD, MDD and PTSD treatment. ALZN002 is a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer's by removing beta-amyloid from the brain through a royalty-bearing exclusive worldwide license from the Licensor.
Company Info
ALZAMEND NEURO INC
480 Peachtree Road Ne, Second Floor, Suite 103
Atlanta GEORGIA US
CEO: Stephan Jackman
Employees: 4
Phone: 18447226333
ALZAMEND NEURO INC / ALZN FAQ
What is the stock price of ALZAMEND NEURO INC today?
The current stock price of ALZN is 2.35 USD. The price increased by 5.86% in the last trading session.
What is the ticker symbol for ALZAMEND NEURO INC stock?
The exchange symbol of ALZAMEND NEURO INC is ALZN and it is listed on the Nasdaq exchange.
On which exchange is ALZN stock listed?
ALZN stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ALZAMEND NEURO INC stock?
8 analysts have analysed ALZN and the average price target is 42.84 USD. This implies a price increase of 1722.98% is expected in the next year compared to the current price of 2.35. Check the ALZAMEND NEURO INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ALZAMEND NEURO INC worth?
ALZAMEND NEURO INC (ALZN) has a market capitalization of 8.93M USD. This makes ALZN a Nano Cap stock.
How many employees does ALZAMEND NEURO INC have?
ALZAMEND NEURO INC (ALZN) currently has 4 employees.
What are the support and resistance levels for ALZAMEND NEURO INC (ALZN) stock?
ALZAMEND NEURO INC (ALZN) has a support level at 2.2 and a resistance level at 2.37. Check the full technical report for a detailed analysis of ALZN support and resistance levels.
Should I buy ALZAMEND NEURO INC (ALZN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ALZN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ALZN, evaluating the profitability, health, valuation and growth aspects
- ALZAMEND NEURO INC (ALZN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ALZAMEND NEURO INC (ALZN) Sales and EPS estimates to see what analysts future expectations are.
- ALZAMEND NEURO INC (ALZN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ALZAMEND NEURO INC (ALZN) Insider and Institutional Ownership to learn about the owners and their transactions.
- ALZAMEND NEURO INC (ALZN) Stock Chart to make your own analysis
- ALZAMEND NEURO INC (ALZN) Latest news and press-releases to stay up to date.
Does ALZAMEND NEURO INC (ALZN) stock pay dividends?
ALZN does not pay a dividend.
When does ALZAMEND NEURO INC (ALZN) report earnings?
ALZAMEND NEURO INC (ALZN) will report earnings on 2025-12-09.
What is the Price/Earnings (PE) ratio of ALZAMEND NEURO INC (ALZN)?
ALZAMEND NEURO INC (ALZN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-9.02).
What is the Short Interest ratio of ALZAMEND NEURO INC (ALZN) stock?
The outstanding short interest for ALZAMEND NEURO INC (ALZN) is 4.42% of its float. Check the ownership tab for more information on the ALZN short interest.
ALZN Technical Analysis
ALZN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ALZN. ALZN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
ALZN Financial Highlights
Over the last trailing twelve months ALZN reported a non-GAAP Earnings per Share(EPS) of -9.02. The EPS increased by 90.63% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -108.85% | ||
| ROE | -128.89% | ||
| Debt/Equity | 0 |
ALZN Forecast & Estimates
8 analysts have analysed ALZN and the average price target is 42.84 USD. This implies a price increase of 1722.98% is expected in the next year compared to the current price of 2.35.